When the Food and Drug Administration (FDA) approved Biogen 's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. There hadn't been a therapy approved for the disease since 2003. The drug will still have to prove its impact in a follow up study, but that could take years.
No matter how that turns out, the low bar for approval set by the FDA is likely to open the floodgates for Alzheimer's treatments. It has investors in Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSEMKT: ANVS) excited about their candidates, which are currently in clinical trials. Here are three reasons those biotech stocks might offer better gains in the years ahead than Biogen.
Image source: Getty Images.
For further details see:
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments